Dosing of medications in morbidly obese patients in the intensive care unit setting

Intensive Care Medicine

Volumn 30, Issue 1, 2004, Pages 18-32

  Erstad, Brian L ^a  

^a Division of Plant Pathology and Microbiology   (United States)

Author keywords

Dosing; Intensive care; Morbid obesity; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ATROPINE; AZTREONAM; BENZODIAZEPINE DERIVATIVE; BETA LACTAM ANTIBIOTIC; CARDIAC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; FIBRINOLYTIC AGENT; GASTROINTESTINAL AGENT; IMMUNOMODULATING AGENT; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE; NEUROMUSCULAR BLOCKING AGENT; OPIATE; PENICILLIN DERIVATIVE; PHENYTOIN; PROPOFOL; QUINOLINE DERIVATIVE; REMIFENTANIL; SEDATIVE AGENT; THEOPHYLLINE; UNINDEXED DRUG; VANCOMYCIN; VASOACTIVE AGENT;

BLOOD CLOTTING DISORDER; BRADYCARDIA; CARDIOVASCULAR DISEASE; CONVULSION; DATA ANALYSIS; DOSE CALCULATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SOLUBILITY; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; GASTROINTESTINAL DISEASE; HUMAN; HYPOTENSION; IMMUNOPATHOLOGY; INFECTION; INFECTION PREVENTION; INFORMATION RETRIEVAL; INTENSIVE CARE; INTENSIVE CARE UNIT; LOW DRUG DOSE; MEDLINE; MORBID OBESITY; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR DISEASE; NONHUMAN; POSTOPERATIVE PAIN; REVIEW; SEDATION; SIDE EFFECT;

ANALGESICS, OPIOID; ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; ANTICONVULSANTS; BODY WEIGHT; CARDIOVASCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; FIBRINOLYTIC AGENTS; GASTROINTESTINAL AGENTS; HUMANS; INTENSIVE CARE; METABOLIC CLEARANCE RATE; OBESITY, MORBID; PRACTICE GUIDELINES; RESPIRATORY SYSTEM AGENTS;

EID: 0742269741     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-2059-6     Document Type: Review

References (64)

1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez AL, Steingrub JS, Garber GE, Heiterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709
2. Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL (1997) Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 25:1289-1297
3. Zarowitz BJ, Petitta A, Rudis MI, Horst HM, Hyzy R (1996) Bar code documentation of pharmacotherapy services in intensive care units. Pharmacotherapy 16:261-266
4. Roubenoff R, Kehayias JJ (1991) The meaning and measurement of lean body mass. Nutrition Rev 49:163-175
5. Devine BJ (1974) Case number 25: gentamicin therapy. Drug Intell Clin Pharm 8:650-655
6. Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Arlet M (1983) Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm 40:1016-1019
7. World Health Organization (1998) Obesity: preventing and managing the global epidemic, report of a WHO consultation on obesity. Geneva, June 3-5
8. National Heart, Lung and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases (September 1998) Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. NIH Publication No. 98-4083
9. Rand CSW, Kuldau JM, Yost RL (1999) Obesity and post-operative pain. J Psychosom Res 29:43-48
10. Bennett R, Baterhorst R, Graves DA, Foster TS, Griffen WO, Wright BD (1982) Variation in postoperative analgesic requirements in the morbidly obese following gastric bypass surgery. Pharmacotherapy 2:50-53
11. Cheymol G (2000) Effects of obesity on pharmacokinetics. Clin Pharmacokinet 39:215-231
12. James WPT (1976) Research on obesity. Her Majesty's Stationary Office, London
13. Egan TD, Huizinga B, Gupta SK, Jaarsma RL, Sperry RJ, Yee JB, Muir KT (1998) Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 89:562-573
14. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivias S (1993) The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 119:874-881
15. Ellison MJ, Sawyer WT, Mills TC (1989) Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 8:65-68
16. Duplaga BA, Rivers CW, Nutescu E (2001) Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21:218-234
17. Yee JYV, Duffull SB (2000) The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharmacol 56:293-297
18. Wilson SJ, Wilbur K, Burton E, Anderson DR (2001) Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 31:42-48
19. Kovacs MJ, Weir K, MacKinnon K, Keeney M, Brien WF, Cruickshank MK (1998) Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery. Thromb Res 91:137-142
20. Barrett JS, Gibiansky E, Hull RD, Planes A, Pentikis H, Hainer JW, Hua TA, Gastonguay M (2001) Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 39:431-446
21. Priglinger U, Karth GD, Geppert A, Joukhadour C, Berger R, Hulsman M, Pabinger I, Heinz G (2002) Prophylactic anticoagulation with low dose enoxaparin - is the subcutaneous route appropriate in the critically ill? Crit Care Med 29 (suppl):A97
22. Abernethy DR, Greenblatt DJ (1985) Phenytoin disposition in obesity: determination of loading dose. Arch Neurol 42:468-471
23. Houghton GW, Richens A, Leighton M (1975) Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol 2:251-256
24. Traynor AM, Nafziger AN, Bertino JS (1995) Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39:545-548
25. Blouin RA, Mann HJ, Griffen WO, Bauer LA, Record KE (1979) Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 26:508-512
26. Bauer LA, Blouin RA, Griffen WO, Record KE, Bell RM (1980) Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 37:519-522
27. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA (1983) Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24:643-647
28. Buchholz U, Richards C, Murthy R, Arduino M, Pon D, Schwartz W, Fontanilla E, Pegues C, Boghossian N, Peterson C, Kool J, Mascola L, Jarvis WR (2000) Pyrogenic reactions associated with single daily dosing of intravenous gentamicin. Infect Control Hosp Epidemiol 21:771-774
29. Kampmann JP, Klein H, Lumholtz B, Hansen JEM (1984) Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. Clin Pharmacokinet 9:168-176
30. Yost RL, Deredorf H (1986) Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit 8:189-194
31. Mann HJ, Buchwald H (1986) Cefamandole distribution in serum, adipose tissue and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 20:869-873
32. Pories WJ, van Rij AM, Burlingham BT, Fulghum S, Meelbeim D (1981) Prophylactic cefazolin in gastric by-pass surgery. Surgery 90:426-432
33. Forse RA, Karam B, MacLean LD, Christou NV (1989) Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 106:750-757
34. Allard S, Kinzig M, Boivin G, Sorgel F, LaBel M (1993) Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54:368-373
35. Caldwell JB (1994) Intravenous ciprofloxacin dosing in a morbidly obese patient (letter). Ann Pharmacother 28:806
36. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO (1982) Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21:575-580
37. Bauer LA, Black DJ, Lill JS (1998) Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54:621-625
38. Chow MS (1996) Intravenous amiodarone: pharmacology, pharmacokinetics and clinical use. Ann Pharmacother 30:637-643
39. Roden DM (1993) Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 72:45F-50F
40. Abernethy DR, Greenblatt DJ, Smith TW (1981) Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 102:740-744
41. Abernethy DR, Greenblatt DJ (1984) Lidocaine disposition in obesity. Am J Cardiol 53:1183-1186
42. Christoff PB, Conti DR, Naylor C, Jusko WJ (1983) Procainamide disposition in obesity. Drug Intell Clin Pharm 17:516-522
43. Cheymol G, Poirier JM, Corrupt PA, Testa B, Weissenburger J, Levron JC, Snoeck E (1997) Pharmacokinetics of β-adrenoreceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 43:563-570
44. Cheymol G, Poirier JM, Barre J, Pradalier A, Dry J (1987) Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 27:874-879
45. Abernethy DR, Schwartz JB (1988) Verapamil pharmacodynamics and disposition in obese hypertensive patients. J Cardiovasc Pharmacol 11:209-215
46. Davis RL, Quenzer RW, Bozigian HP, Warner CW (1990) Pharmacokinetics of ranitidine in morbidly obese women. DICP Ann Pharmacother 24:1040-1043
47. Abernethy DR, Greenblatt DJ, Matlis R, Gugler R (1984) Cimetidine disposition in obesity. Am J Gastroenterol 79:91-94
48. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, Marshall LF, Perot PL, Piepmeier J, Sonntag VKH, Wagner FC, Wilberger JE, Winn HR (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl J Med 322:1405-1411
49. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VKH, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration of methylprednisolone for 24 or 48 hours or tirilizad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277:1597-1604
50. Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ (1991) Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 49:536-549
51. Varin F, Ducharme J, Theoret Y, Besner YG, Bevan DR, Donati F (1990) Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin Pharmacol Ther 48:18-25
52. Puhringer FK, Keller C, Kleinsasser A, Giesinger S, Benzer A (1999) Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 16:507-510
53. Schwanz AE, Matteo RS, Ornstein E, Halevy JD, Diaz J (1992) Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 74:515-518
54. Gal P, Jusko WJ, Yurchak AM, Franklin BA (1978) Theophylline disposition in obesity. Clin Pharmacol Ther 23:438-444
55. Zahorska-Markiewicz B, Waluga M, Zielinski M, Klin M (1996) Pharmacokinetics of theophylline in obesity. Int J Clin Pharmacol Ther 34:393-395
56. Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI (1981) Alterations in drug distribution and clearance in obesity. J Pharmacol Exp Ther 217:681-685
57. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI (1984) Effect of age, gender and obesity on midazolam kinetics. Anesthesiology 61:27-35
58. Servin F, Farinotti R, Haberer JP, Desmonts JM (1993) Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. Anesthesiology 78:657-665
59. Tsikouris JP, Tsikouris AP (2001) A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 21:207-217
60. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587
61. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274:1017-1025
62. MacGregor DA, Smith TE, Prielipp RC, Butterworth JF, James RL, Scuderi PE (2000) Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 92:338-346
63. Klem C, Dasta JF, Reilley TE, Flancbaum LJ (1994) Variability of dobutamine pharmacokinetics in unstable critically ill patients. Crit Care Med 22:1926-1932
64. Steinberg C, Notterman DA (1994) Pharmacokinetics of cardiovascular drugs in children: inotropes and vasopressors. Clin Pharmacokinet 27:345-367